The mechanism of resistance to anti‐PD‐1/PD‐L1 therapy is unclear but might be because the tumor immune microenvironment (TIME) in DLBCL is not simple, and the interaction of very complex factors is intertwined. The gene discussed is PDCD1; the disease is neoplasm.